Literature DB >> 6454387

Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects.

W M Scheld, D A Spyker, G R Donowitz, W K Bolton, M A Sande.   

Abstract

Moxalactam, a new beta-lactam antibiotic with a wide in vitro spectrum of activity, was compared with cefazolin after intravenous and intramuscular administration of 1.0 g in a double-blind crossover design in 21 adult male subjects with normal renal function. Serum samples were obtained at 0.5, 1, 2, 3, 4, 6, 8, and 12 h, and urine was collected at 0 to 2, 2 to 4, 4 to 6, 6 to 8, and 8 to 12 h after dosing. Intravenous kinetics were described by a linear two-compartment model. For moxalactam, the drug clearance and volume of distribution were larger (115.2 versus 75.9 ml/min per 70 kg, P = 0.001, and 0.44 versus 0.19 liter/kg, P less than 0.001, respectively), and the t1/2beta was longer (3.47 versus 2.18 h, P = 0.01), with correspondingly smaller area under the curve (151 versus 236 h x mg/ml, P = 0.003) and lower serum concentration at 30 min (62 versus 106 micrograms/ml, P = 0.003) than cefazolin. Intramuscular kinetics were similar and were well described by a single-compartment model. Urinary recovery was essentially identical for both drugs: 55 to 75% in 8 h. Consistent departures from the two-compartment model for moxalactam (not noted for cefazolin) suggested enterohepatic recirculation of moxalactam. Both drugs were well tolerated, and no adverse reactions were noted.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6454387      PMCID: PMC181488          DOI: 10.1128/AAC.19.4.613

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Gentamicin serum concentrations: pharmacokinetic predictions.

Authors:  J H Hull; F A Sarubbi
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

3.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

4.  Response model analysis for cross-fostering studies: prenatal versus postnatal effects on offspring exposed to methylmercury dicyandiamide.

Authors:  D A Spyker; J M Spyker
Journal:  Toxicol Appl Pharmacol       Date:  1977-06       Impact factor: 4.219

5.  Gentamicin dosage.

Authors: 
Journal:  Ann Intern Med       Date:  1977-03       Impact factor: 25.391

6.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

7.  Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration.

Authors:  D A Spyker; R J Rugloski; R L Vann; W M O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

8.  LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

9.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  Clinical and in vitro evaluation of cefazolin, a new cephalosporin antibiotic.

Authors:  K Ries; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

View more
  18 in total

1.  Prediction of Clearance and Volume of Distribution in the Obese from Normal Weight Subjects : An Allometric Approach.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

2.  Pharmacokinetics and pharmacogenomics of β-lactam-induced neutropenia.

Authors:  Andrea Hahn; Tsuyoshi Fukuda; David Hahn; Tomoyuki Mizuno; Robert W Frenck; Alexander A Vinks
Journal:  Pharmacogenomics       Date:  2016-04-05       Impact factor: 2.533

3.  Effect of probenecid on the pharmacokinetics of moxalactam.

Authors:  K A DeSante; K S Israel; G L Brier; J D Wolny; B L Hatcher
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

4.  Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.

Authors:  K S Israel; H R Black; G L Brier; J D Wolny; K A DeSante
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

5.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

6.  Effects of general and local anesthesia on the pharmacokinetics of cefazolin in patients undergoing orthopedic surgery.

Authors:  W D Welch; J P Jantzen; K Johnson; R E Bawdon
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

8.  Comparative pharmacokinetics of ceftazidime and moxalactam.

Authors:  T B Tjandramaga; A Van Hecken; A Mullie; R Verbesselt; P J De Schepper; L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 10.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.